| Autor: |
MIKYUNG KIM |
| Předmět: |
|
| Zdroj: |
Food & Drug Law Journal; 2014, Vol. 69 Issue 4, p603-623, 21p |
| Abstrakt: |
The article discusses the author's claim that following the approval of a drug by the U.S. Food and Drug Administration (FDA), pharmacogenomics can complement the use of pharmacologic class effects in drug-safety management by explaining the severity of adverse effects and drug interactions within a specific class of drugs. The FDA's regulation of new molecular entities (NMEs) is addressed in relation "Boxed Warning" (black box warning) labels. The practice of medicine is also examined. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
